Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Sees Significant Decline in Short Interest

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) saw a significant decrease in short interest in November. As of November 15th, there was short interest totalling 55,000 shares, a decrease of 15.4% from the October 31st total of 65,000 shares. Based on an average daily volume of 323,700 shares, the short-interest ratio is presently 0.2 days. Approximately 3.9% of the shares of the stock are sold short.

Salarius Pharmaceuticals Stock Performance

Shares of NASDAQ:SLRX opened at $1.43 on Monday. The business’s fifty day moving average price is $1.53 and its two-hundred day moving average price is $2.16. The stock has a market cap of $2.06 million, a PE ratio of -0.18 and a beta of 0.93. Salarius Pharmaceuticals has a one year low of $1.26 and a one year high of $7.27.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.